- Home
- QUIK vs CRBP Comparison
QUIK vs CRBP Comparison
Compare QUIK & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- CRBP
- Stock Information
- Founded
- QUIK 1988
- CRBP 2009
- Country
- QUIK United States
- CRBP United States
- Employees
- QUIK N/A
- CRBP N/A
- Industry
- QUIK Semiconductors
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- QUIK Technology
- CRBP Health Care
- Exchange
- QUIK Nasdaq
- CRBP Nasdaq
- Market Cap
- QUIK 100.1M
- CRBP 110.3M
- IPO Year
- QUIK 1997
- CRBP N/A
- Fundamental
- Price
- QUIK $6.17
- CRBP $9.31
- Analyst Decision
- QUIK Strong Buy
- CRBP Strong Buy
- Analyst Count
- QUIK 3
- CRBP 10
- Target Price
- QUIK $10.87
- CRBP $53.56
- AVG Volume (30 Days)
- QUIK 185.6K
- CRBP 128.8K
- Earning Date
- QUIK 08-12-2025
- CRBP 08-12-2025
- Dividend Yield
- QUIK N/A
- CRBP N/A
- EPS Growth
- QUIK N/A
- CRBP N/A
- EPS
- QUIK N/A
- CRBP N/A
- Revenue
- QUIK $18,768,000.00
- CRBP N/A
- Revenue This Year
- QUIK $11.58
- CRBP N/A
- Revenue Next Year
- QUIK $40.23
- CRBP $270.04
- P/E Ratio
- QUIK N/A
- CRBP N/A
- Revenue Growth
- QUIK N/A
- CRBP N/A
- 52 Week Low
- QUIK $4.26
- CRBP $4.64
- 52 Week High
- QUIK $13.36
- CRBP $61.89
- Technical
- Relative Strength Index (RSI)
- QUIK 48.53
- CRBP 62.56
- Support Level
- QUIK $6.13
- CRBP $9.00
- Resistance Level
- QUIK $6.77
- CRBP $10.06
- Average True Range (ATR)
- QUIK 0.35
- CRBP 0.58
- MACD
- QUIK -0.04
- CRBP 0.07
- Stochastic Oscillator
- QUIK 26.57
- CRBP 63.21
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.